vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Down 24.9% in December

vTv Therapeutics Inc. (NASDAQ:VTVT) was the target of a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 16,900 shares, a drop of 24.9% from the November 30th total of 22,500 shares. Approximately 1.1% of the shares of the company are sold short. Based on an average daily volume of 29,300 shares, the short-interest ratio is currently 0.6 days.

vTv Therapeutics Price Performance

Shares of NASDAQ:VTVT traded down $0.33 during midday trading on Friday, hitting $13.20. The company had a trading volume of 2,926 shares, compared to its average volume of 36,416. The company has a market cap of $42.11 million, a price-to-earnings ratio of -2.91 and a beta of 0.67. The company has a fifty day moving average of $15.02 and a two-hundred day moving average of $16.05. vTv Therapeutics has a 12-month low of $7.38 and a 12-month high of $30.99.

Hedge Funds Weigh In On vTv Therapeutics

An institutional investor recently bought a new position in vTv Therapeutics stock. FMR LLC bought a new position in vTv Therapeutics Inc. (NASDAQ:VTVT) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 178,200 shares of the biotechnology company’s stock, valued at approximately $2,402,000. FMR LLC owned 5.92% of vTv Therapeutics as of its most recent filing with the SEC. 17.51% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Alliance Global Partners started coverage on shares of vTv Therapeutics in a research report on Monday, December 9th. They set a “buy” rating and a $35.00 price target for the company.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.